Workers in hazardous workplaces are facing allegations that they received chelation therapy to artificially lower their blood metal levels before mandatory health assessments. The government has initiated an investigation into these claims, aiming to uncover whether the treatments were administered indiscriminately without medical justification to distort test results.
The Ministry of Health and Welfare announced that from November 10 to 16, it will conduct a joint administrative investigation into two medical institutions suspected of providing abnormal treatments related to chelation therapy. This investigation follows concerns raised during a National Assembly audit on October 27, which prompted the identification of these two facilities based on tip-offs.
The controversial chelation therapy involves administering agents that bind to heavy metals like lead, mercury, and cadmium, facilitating their excretion through urine. Originally intended for treating acute and chronic heavy metal poisoning under strict medical supervision, it is now under scrutiny for potential misuse.
Concerns center on the allegation that this treatment was exploited as a means to conceal occupational diseases rather than to promote workers' health. Reports suggest that some medical institutions, linked to specific workplaces, conducted preliminary blood lead tests on workers and then administered chelation therapy up to five times before the legally mandated special health examinations in February and March of the following year. This was allegedly done to avoid diagnoses of lead poisoning.
On October 23, the Korean Medical Association expressed its concern, stating that inappropriate use of medications that threaten public health must be eradicated.
The Ministry's investigation team will focus on several key areas: whether there was a medical basis for administering chelation therapy based on individual blood lead tests and symptoms, the appropriateness of the drugs used, dosages, and administration intervals, and whether underlying conditions such as kidney disease were verified prior to treatment. They will also examine the correlation between the timing of the special health examinations and the administration of the therapy.
Additionally, the investigation will assess whether the stated purpose of the treatment aligns with the medical records and whether patients were adequately informed about the purpose and potential side effects of the injections. If any violations of medical laws, such as collusion with workplaces to recruit patients, improper health insurance claims, or false advertising are detected during the investigation, they will also be addressed.
Furthermore, the Ministry plans to seek official consultation from the Korean Medical Association based on the findings of the investigation to determine whether the administration of chelation therapy by these medical institutions met medical standards. This expert consultation model will be broadly applied to future investigations into excessive or abnormal medical practices.
Gwak Soon-hun, head of the Ministry's investigation team, emphasized, “Medical practices should protect the health and lives of patients, and they must not be used to distort health examination results or conceal occupational diseases. We will thoroughly verify the medical appropriateness of chelation therapy and its relation to special health examinations to rectify abnormal practices in the medical field.”
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.